PSYCHOPHARMACOLOGY OF PEDIATRIC BIPOLAR DISORDER

儿科双相情感障碍的精神药理学

• 批准号: 6391612
• 负责人: DAVID A AXELSON
• 金额: $ 13.62万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-05-01 至 2005-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6391612
• 关键词: adolescence (12-20); antidepressants; behavioral /social science research tag; bipolar depression; bipolar depression manic phase; child (0-11); clinical research; clinical trials; combination chemotherapy; dosage; drug screening /evaluation; human subject; human therapy evaluation; lithium; longitudinal human study; mental disorder chemotherapy; pediatric pharmacology; psychopharmacology; relapse /recurrence; serotonin inhibitor; sign /symptom; valproate

The career development activities and research plan outlined in this Research Career Development Award (RCA) are designed to provide the means for the candidate to translate relevant aspects of neurobiology and independently formulate and implement psychopharmacologic treatment trials in pediatric bipolar disorder (BP). Pediatric BP is a devastating illness that can result in permanent disruption of a child's normal development, emotional suffering, aggression and suicide. Pharmacotherapy has been the cornerstone of the management and treatment of pediatric BP. However, there is very little controlled research addressing medication treatment of children and adolescents with BP. In addition, treatment research in child psychiatry has generally not addressed developmental differences in neurobiology or pharmacology, nor attempted to identify biological factors that may be predictors or mediators of treatment response. The proposed study will be the first dose-ranging study of a medication for depression in pediatric BP. It will explore the relationship between platelet 5-HT reuptake blockade and treatment response, as well as examine potential predictors of treatment response. The candidate is certified in child and adolescent psychiatry, and is completing the second year of an NIMH-sponsored post-doctoral research fellowship. Dr. James Perel, Professor of Psychiatry and Pharmacology and Director of the Clinical Pharmacology Program at the University of Pittsburgh's Western Psychiatric Institute and Clinic (WPIC) will serve as Sponsor. The coursework and directed readings in advanced topics of psychopharmacology, clinical trial design, developmental neurobiology and pharmacology, emotional regulation and circadian rhythm, will prepare the candidate to perform biologically-informed treatment research in pediatric BP.

本研究职业发展奖（RCA）中概述的职业发展活动和研究计划旨在为候选人提供翻译神经生物学相关方面的手段，并独立制定和实施儿科躁郁症（BP）中的心理药物治疗试验。 小儿BP是一种毁灭性的疾病，可能导致儿童正常发育，情感痛苦，侵略和自杀的永久破坏。 药物治疗一直是小儿BP管理和治疗的基石。 但是，对BP儿童和青少年的药物治疗的受控研究很少。 此外，儿童精神病学的治疗研究通常没有解决神经生物学或药理学方面的发育差异，也没有试图识别可能是治疗反应的预测因素或介体的生物学因素。 拟议的研究将是小儿BP抑郁症药物的首次剂量范围研究。 它将探索血小板5-HT再摄取阻滞与治疗反应之间的关系，并检查治疗反应的潜在预测指标。 该候选人获得了儿童和青少年精神病学的认证，并且正在完成NIMH赞助的博士后研究奖学金的第二年。 匹兹堡大学西方精神病学研究所和诊所（WPIC）的精神病学和药理学教授兼临床药理学计划主任詹姆斯·佩雷尔（James Perel）博士将担任赞助商。 心理药理学，临床试验设计，发育神经生物学和药理学，情绪调节和昼夜节律的课程工作和定向阅读将使候选人做好准备在儿科BP中进行生物学知名治疗研究。